On 24 May, Azierta, a consultancy firm specialising in science and health, organised the ‘Science to Business: Successful case studies in the development of innovators and biosimilars’ event in Barcelona. The aim of this event was to look at different successful case studies in the development of innovative and biosimilar products in order to analyse the relationship between science and the business world, as well as the impact this new type of products is having on the pharmaceutical market.
Representatives from two of Spain’s leading companies in terms of innovators and biosimilars participated in the event: Susana Millán, Medical & RA Director at mAbxience, a biotechnology company belonging to the Chemo group that specialises in the research, development and production of biological medications (mainly biosimilars), and César Molinero, Medical and Operational Director at Clínicas de Oryzon, a clinical phase biopharmaceutical company that specialises in the creation and development of innovative epigenetic therapies for patients with cancer and neurodegenerative disorders. Also in attendance were Chelo Tudela, Senior Preclinical & Clinical Regulatory Specialist, and Ángel Navarro, CEO of Azierta, who gave a presentation and acted as moderator of the debate.
Susana Millán explained that mAbxience, which belongs to the umbrella company Chemo and follows the same business model, is: “a B2B company that develops the complete product in order to subsequently licence it to other companies, whereby mAbxience is responsible for R&D and production, but leaves the marketing to third parties”. mAbxience, created in 2009, marketed their first biosimilar in Argentina in 2014, based around Rituximab. They have recently signed a project with the WHO and the Andrés Bello Catholic University in Venezuela to develop Palivizumab, biosimilar of Synagis.
Millán highlighted that mAbxience follows the ‘Fingerprint Like’ philosophy, which “focuses on investment in R&D in search of a product that most closely matches the reference product”, and confirmed that the primary objective of the company is to ensure that they have done their homework come 2020, when there will be a large-scale loss of patents.
The session concluded with a lively debate between attendees on the potential pros and cons, which served to emphasise the ever-growing interest in this sector and that more than a future vision, biosimilars have already arrived.
*This article was published by PMFarma. The original is available here